Preexisting insulin autoantibodies predict efficacy of otelixizumab in preserving residual b-Cell function in recent-onset type 1 diabetes

Diabetes Care

Volumn 38, Issue 4, 2015, Pages 644-651

  Demeester, Simke ^a   Keymeulen, Bart ^a   Kaufman, Leonard ^a   Van Dalem, Annelien ^a   Balti, Eric V ^a   Van De Velde, Ursule ^a   Goubert, Patrick ^a   Verhaeghen, Katrijn ^a   Davidson, Howard W ^b   Wenzlau, Janet M ^b   Weets, Ilse ^a   Pipeleers, Daniel G ^a   Gorus, Frans K ^a  

^a DIABETES RESEARCH CENTER   (Belgium)

^b UNIVERSITY OF COLORADO DENVER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; C PEPTIDE; CARRIER PROTEIN; CELL PROTEIN; GADA AUTOANTIBODY; HEMOGLOBIN A1C; INSULIN; INSULIN (GADA); INSULIN (IAA); INSULIN AUTOANTIBODY; INSULINOMA ASSOCIATED PROTEIN 2; INSULINOMA ASSOCIATED PROTEIN 2 AUTOANTIBODY; OTELIXIZUMAB; PLACEBO; UNCLASSIFIED DRUG; ZINC TRANSPORTER 8A; ZINC TRANSPORTER 8A AUTOANTIBODY; BIOLOGICAL MARKER; INSULIN ANTIBODY; MONOCLONAL ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PHASE 2 CLINICAL TRIAL; PREDICTION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; RANDOMIZED CONTROLLED TRIAL; RECENT-ONSET TYPE 1 DIABETES; TREATMENT DURATION; ADOLESCENT; BLOOD; CHILD; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOMARKERS; CHILD; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; INSULIN; INSULIN ANTIBODIES; INSULIN-SECRETING CELLS; MALE; PROGNOSIS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84962168905     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-1575     Document Type: Article

References (38)

1. Gorus FK, Keymeulen B, Veld PA, Pipeleers DG. Predictors of progression to Type 1 diabetes: preparing for immune interventions in the preclinical disease phase. Expert Rev Clin Immunol 2013;9:1173-1183.
2. Herold KC, Hagopian W, Auger JA, et al. Anti- CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl JMed 2002;346:1692-1698.
3. Sherry N, Hagopian W, Ludvigsson J, et al.; Protege Trial Investigators. Teplizumab for treatment of type 1 diabetes (Proteǵe study): 1-year results from a randomised, placebocontrolled trial. Lancet 2011;378:487-497.
4. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005;352:2598-2608.
5. Keymeulen B, Walter M, Mathieu C, et al. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 2010;53:614-623.
6. Skyler JS, Ricordi C. Stopping type 1 diabetes: Attempts to prevent or cure type 1 diabetes in man. Diabetes 2011;60:1-8.
7. Ludvigsson J; Linkoping Diabetes Immune Intervention Study Group. The role of immunomodulation therapy in autoimmune diabetes. J Diabetes Sci Tech 2009;3:320-330.
8. Herold KC, Gitelman SE, Ehlers MR, et al.; AbATE Study Team. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes 2013;62:3766- 3774.
9. Piemonti L, Everly MJ, Maffi P, et al. Alloantibody and autoantibody monitoring predicts islet transplantation outcome in human type 1 diabetes. Diabetes 2013;62:1656-1664.
10. Vehik K, Cuthbertson D, Ruhlig H, Schatz DA, Peakman M, Krischer JP; DPT-1 and TrialNet Study Groups. Long-term outcome of individuals treated with oral insulin: diabetes prevention trial (DPT-1) oral insulin trial. Diabetes Care 2011;34:1585-1590.
11. Ludvigsson J, Binder C, Mandrup-Poulsen T. Insulin autoantibodies are associated with islet cell antibodies; their relation to insulin antibodies and B-cell function in diabetic children. Diabetologia 1988;31:647-651.
12. Gorus FK. Diabetes registries and early biological markers of insulin-dependent diabetes mellitus. Diabetes Metab Rev 1997;13:247-274.
13. Wenzlau JM, Walter M, Gardner TJ, et al. Kinetics of the post-onset decline in zinc transporter 8 autoantibodies in type 1 diabetic human subjects. J Clin Endocrinol Metab 2010;95: 4712-4719.
14. Gorus FK, Sodoyez JC, Pipeleers DG, Keymeulen B, Foriers A, Van Schravendijk CF. Detection of autoantibodies against islet amyloid polypeptide in human serum. Lack of association with type 1 (insulin-dependent) diabetes mellitus, or with conditions favouring amyloid deposition in islets. The Belgian Diabetes Registry. Diabetologia 1992;35:1080-1086.
15. Srikanta S, Ricker AT, McCulloch DK, Soeldner JS, Eisenbarth GS, Palmer JP. Autoimmunity to insulin, beta cell dysfunction, and development of insulin-dependent diabetes mellitus. Diabetes 1986;35:139-142.
16. Greenbaum CJ, Palmer JP, Kuglin B, Kolb H. Insulin autoantibodies measured by radioimmunoassay methodology are more related to insulin-dependent diabetes mellitus than those measured by enzyme-linked immunosorbent assay: results of the Fourth International Workshop on the Standardization of Insulin Autoantibody Measurement. J Clin Endocrinol Metab 1992;74:1040-1044.
17. Franke B, Galloway TS, Wilkin TJ. Developments in the prediction of type 1 diabetesmellitus, with special reference to insulin autoantibodies. Diabetes Metab Res Rev 2005;21:395-415.
18. De Grijse J, Asanghanwa M, Nouthe B, et al.; Belgian Diabetes Registry. Predictive power of screening for antibodies against insulinomaassociated protein 2 beta (IA-2beta) and zinc transporter-8 to select first-degree relatives of type 1 diabetic patients with risk of rapid progression to clinical onset of the disease: implications for prevention trials. Diabetologia 2010; 53:517-524.
19. Lernmark A, Kolb H, Mire-Sluis T. Towards a World Health Organization (WHO) approved standard sample for islet cell antibodies, GAD65 and IA-2 autoantibodies. Diabetologia 1999;42:381-382.
20. Wenzlau JM, Juhl K, Yu L, et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A 2007;104:17040-17045.
21. Williams AJ, Norcross AJ, Chandler KA, Bingley PJ. Non-specific binding to protein A Sepharose and protein G Sepharose in insulin autoantibody assays may be reduced by pretreatment with glycine or ethanolamine. J Immunol Methods 2006;314:170-173.
22. Hale G, Rebello P, Al Bakir I, et al. Pharmacokinetics and antibody responses to the CD3 antibody otelixizumab used in the treatment of type 1 diabetes. J Clin Pharmacol 2010;50:1238-1248.
23. Palmer JP. C-peptide in the natural history of type 1 diabetes. Diabetes Metab Res Rev 2009;25:325-328.
24. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-E223.
25. Jasinski JM, Eisenbarth GS. Insulin as a primary autoantigen for type 1A diabetes. Clin Dev Immunol 2005;12:181-186.
26. Pipeleers D, Ling Z. Pancreatic beta cells in insulin-dependent diabetes. Diabetes Metab Rev 1992;8:209-227.
27. Steck AK, Johnson K, Barriga KJ, et al. Age of islet autoantibody appearance and mean levels of insulin, but not GAD or IA-2 autoantibodies, predict age of diagnosis of type 1 diabetes: diabetes autoimmunity study in the young. Diabetes Care 2011;34:1397-1399.
28. Yu L, Herold K, Krause-Steinrauf H, et al.; Type 1 Diabetes TrialNet Anti-CD20 Study Group. Rituximab selectively suppresses specific islet antibodies. Diabetes 2011;60:2560-2565.
29. Atkinson MA. The pathogenesis and natural history of type 1 diabetes. Cold Spring Harb Perspect Med 2012;2:a007641.
30. Kent SC, Chen Y, Bregoli L, et al. Expanded T cells from pancreatic lymph nodes of type 1 650 IAA Predict Otelixizumab Efficacy Diabetes Care Volume 38, April 2015 diabetic subjects recognize an insulin epitope. Nature 2005;435:224-228.
31. Martin S, Wolf-Eichbaum D, Duinkerken G, et al. Development of type 1 diabetes despite severe hereditary B-lymphocyte deficiency. N Engl J Med 2001;345:1036-1040.
32. Chatenoud L, Warncke K, Ziegler AG. Clinical immunologic interventions for the treatment of type 1 diabetes. Cold Spring Harb Perspect Med 2012;2:a007716.
33. Pescovitz MD, Greenbaum CJ, Krause- Steinrauf H, et al.; Type 1 Diabetes TrialNet Anti-CD20 Study Group. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009;361:2143-2152.
34. Mamchak AA, Manenkova Y, Leconet W, et al. Preexisting autoantibodies predict efficacy of oral insulin to cure autoimmune diabetes in combination with anti-CD3. Diabetes 2012;61:1490-1499.
35. Balti EV, Vandemeulebroucke E, Weets I, et al. Hyperglycemic clamp and oral glucose tolerance test for 3-year prediction of clinical onset in persistently autoantibody-positive offspring and siblings of type 1 diabetic patients. J Clin Endocrinol Metab. 18 November 2014 [Epub ahead of print].
36. Vandemeulebroucke E, Keymeulen B, Decochez K, et al.; Belgian Diabetes Registry. Hyperglycaemic clamp test for diabetes risk assessment in IA-2-antibody-positive relatives of type 1 diabetic patients. Diabetologia 2010;53:36-44.
37. Keymeulen B, Gillard P, Mathieu C, et al. Correlation between beta cellmass and glycemic control in type 1 diabetic recipients of islet cell graft. Proc Natl Acad Sci U S A 2006;103:17444-17449.
38. Piemonti L, Maffi P, Monti L, et al. Beta cell function during rapamycin monotherapy in long-term type 1 diabetes. Diabetologia 2011; 54:433-439.